Balanced news tone
News Sentiment
9969 sentiment intelligence
InnoCare Pharma Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
73/100 classification confidence.
directly relevant articles
high-authority source matches
+6.9% over one week, +25.9% over four weeks, trend inactive, and materially above fair value.
InnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
InnoCare Pharma (SEHK:9969) Is Up 6.6% After First CDH17 ADC Enters Human Trials
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 10:21
- Source
- simplywall.st
INNOCARE (09969) Stock Forum and Discussion
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jul 2026 07:45
- Source
- Moomoo
Is InnoCare Pharma (SEHK:9969) Undervalued On Its Breakthrough Lupus Trial Results?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 10 Jul 2026 22:20
- Source
- simplywall.st
Extensive Orelabrutinib Data Across Regions Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- simplywall.st
InnoCare Pharma Limited Just Missed Revenue By 19%: Here's What Analysts Think Will Happen Next
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 26 Apr 2026 07:00
- Source
- simplywall.st
InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock Upside
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 30 Mar 2026 07:00
- Source
- Sahm
InnoCare Pharma posts 134% revenue surge in 2025, recording annual profit for first time
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 02 Feb 2026 08:00
- Source
- China Daily
InnoCare, Keymed sell ex-China rights for bispecific to RTW-built biotech in $520M deal
- Tone
- Negative 34/100
- Event
- Deals and strategy
- Published
- 21 Jan 2025 08:00
- Source
- Fierce Biotech
Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2021 07:00
- Source
- Biogen